retatrutide clinical trial results weight loss retatrutide Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a New GLP-1 obesity drug, retatrutide,

In Europe, new medications and health treatments are approved first by governments or public institutions and only when theyve received the green light, are companies able to fully commercialise them. Meanwhile, things are more commercially driven in the US, with less stringent regulation

Regehr WG, Tank DW (1991)

These enzymes contribute to the epigenetic regulation of gene expression by catalyzing reactions involved in the demethylation of DNA and histones

H., Guz, Y., Grigoryan, M

Glutathione is not a "magic pill" that will drastically change your skin color in a week

ZepBound, launched for obesity in late 2023, quickly added hundreds of millions in sales by mid-2025, its global sales were already in the hundreds of millions as clinics rolled out the new weight-loss injection